About Us
Fresenius Kabi at a glance
Our product portfolio comprises a range of highly complex biopharmaceuticals, clinical nutrition, medical technologies, and I.V. generic drugs. Within biopharmaceuticals, Fresenius Kabi offers, among others, biosimilar drugs with a focus on autoimmune diseases and oncology. Our clinical nutrition offering includes a wide selection of enteral and parenteral nutrition products. In the segment of medical technologies, Fresenius Kabi offers vital disposables, infusions pumps, apheresis machines, cell therapy devices, and more.
Fresenius Kabi employs around 42,000 people worldwide.
With our corporate mission of "caring for life", we put essential medicines and technologies in the hands of people who help patients and find the best answers to the challenges they face.
Following our “Vision 2026”, we are furthermore committed to increase efficiencies in the therapy and care of patients and improve access to high-quality healthcare around the globe. We aspire to be leading globally in our product segments – all for the benefit of patients, our customers, and our stakeholders.
In 2022, we reported sales of more than €7.8 billion. Fresenius Kabi AG is a wholly owned subsidiary of the Fresenius SE & Co. KGaA healthcare group.
Key Figures
| € in millions | 2022 | 2021 |
|---|---|---|
| Revenue | 7,850 | 7,193 |
| EBITDA1 | 1,576 | 1,601 |
| EBIT1 | 1,080 | 1,153 |
| Net Income1,2 | 780 | 778 |
| Employees (Dec 31) | 42,063 | 41,397 |
1 Before special items
2 Net income attributable to shareholders of Fresenius SE & Co. KGaA